After nearly a decade of research and
development, BioSig Tech could be poised to break into the nearly $5 billion
global electrophysiology market.
In the spring of 2018, the West Los
Angeles-based medical device company has filed for federal approval for a medical device that can help doctors target the cells that cause arrhythmias,
or irregular heartbeats, which increase the risks of cardiac problems and
stroke.
This biomedical device, called PURE EP, aims to cut
through the background noise of the operating room and its equipment in order
to allow doctors to pinpoint parts of the heart that cause atrial fibrillation
and ventricular tachycardia.
